title: Low-Dose 0.5% 5-Fluorouracil/10% Salicylic Acid Topical Solution in the Treatment of Actinic Keratoses.
abstract: BACKGROUND
  Actinic keratosis (AK) lesions have the potential to develop into invasive squamous cell carcinomas (SCCs), and approaches to treatment are evolving to try to reduce the burden of SCC.
  
  
  OBJECTIVE
  To present the published clinical research surrounding the use of 0.5% 5-fluorouracil with 10% salicylic acid (low-dose 5-FU/SA) for the treatment of hyperkeratotic AKs.
  
  
  METHODS
  A review of published clinical evidence for low-dose 5-FU/SA for the treatment of AKs. The articles were selected following a MEDLINE database search of the combined terms fluorouracil, salicylic acid and actinic keratosis which represent the peer review publications of clinical studies that primarily investigate the use of Actikerall in AK.
  
  
  RESULTS
  Combining low-dose 5-FU with keratolytic SA is associated with high rates of histologic clearance, reduction in lesion number/area, and sustained clinical response in clinical study and the clinical practice setting. Low-dose 5-FU/SA has also been evaluated using imaging to detect the progression of subclinical AK lesions through a course of the field-directed treatment.
  
  
  CONCLUSIONS
  Low-dose 5-FU/SA is an effective and well-tolerated treatment option licensed for the lesion-directed treatment of mild-to-moderate hyperkeratotic AK lesions.
authors.affiliation: Department of Dermatology, La Paz University Hospital, Madrid, Spain pherranzp@gmail.com.
authors.forename: Pedro
authors.initials: P
authors.lastname: Herranz
authors.affiliation: Forth Valley Dermatology Centre, Stirling Community Hospital, NHS Forth Valley, Stirling, UK.
authors.forename: Colin
authors.initials: C
authors.lastname: Morton
authors.affiliation: Private Dermatological Practice Centre, Wuppertal, and Faculty of Health, Witten/Herdecke University, Witten, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Dirschka
authors.affiliation: Almirall S.A., Barcelona, Spain.
authors.forename: Rosario Rodríguez
authors.initials: RR
authors.lastname: Azeredo
authors.affiliation: Faculty of Medicine, Universidad Nacional Autónoma de México, and Hospital San Angel Inn Universidad, Mexico City, Mexico.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Roldán-Marín
mesh_terms: D000279:Administration, Cutaneous; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D004338:Drug Combinations; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage*; D055623:Keratosis, Actinic / Q000188:drug therapy*; D020156:Salicylic Acid / Q000008:administration & dosage*; D012996:Solutions
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D007641:Keratolytic Agents; D012996:Solutions; D020156:Salicylic Acid; D005472:Fluorouracil
keywords: cancer; keratinization